Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index; 41 of the 118 sources its claims cite were checked for support.

Nanosensitizer-assisted sonodynamic therapy for breast cancer

Open access
Yu, Jing, Hu, Jun-Rui, Tian, Yi, Lei, Yu-Meng, Hu, Hai-Man, Lei, Bing-Song, Zhang, Ge, Sun, Yao, Ye, Hua-Rong · 2025 · Journal of Nanobiotechnology

Abstract

Breast cancer is the most commonly diagnosed cancer worldwide. Despite advancements in therapeutic modalities, its prognosis remains poor owing to complex clinical, pathological, and molecular characteristics. Sonodynamic therapy (SDT) is a promising approach for tumor elimination, using sonosensitizers that preferentially accumulate in tumor tissues and are activated by low-intensity ultrasound to produce reactive oxygen species. However, the clinical translation of SDT faces challenges, including the limited efficiency of sonosensitizers and resistance posed by the tumor microenvironment. The emergence of nanomedicine offers innovative strategies to address these obstacles. This review discusses strategies for enhancing the efficacy of SDT using sonosensitizers, including rational structural modifications, improved tumor-targeted enrichment, tumor microenvironment remodeling, and imaging-guided therapy. Additionally, SDT-based multimodal therapies, such as sono-chemotherapy, sono-immunotherapy, and sono-photodynamic therapy, and their potential applications in breast cancer treatment are summarized. The underlying mechanisms of SDT in breast cancer are briefly outlined. Finally, this review highlights current challenges and prospects for the clinical translation of SDT, providing insights into future advancements that may improve therapeutic outcomes for breast cancer.

Overview

CoChat Summary

## TL;DR

This is a review of nanosensitizer-assisted sonodynamic therapy (SDT) for breast cancer, summarizing how nanomaterials can improve tumor targeting, overcome microenvironmental resistance, and enable combination therapies. The paper argues that SDT is promising but still largely preclinical for breast cancer, with clinical translation limited by sonosensitizer performance, tumor microenvironment barriers, and lack of standardization.

## Key findings

  • SDT uses low-intensity ultrasound to activate sonosensitizers that preferentially accumulate in tumors and generate reactive oxygen species (ROS); the review notes commonly used ultrasound ranges of 0.5 to 5 Wcm−2 and 0.035 to 3 MHz.
  • The paper states that breast-cancer SDT is still mainly in the preclinical stage, and that current limitations include low ROS production efficiency, poor tumor targeting, hypoxia, and high glutathione (GSH) in the tumor microenvironment.
  • Examples summarized in the review report strong preclinical effects, including 92.21% tumor volume inhibition for PSDL + US versus 53.59% for SRA737/DOX alone, and 70.35% tumor inhibition for Cu/TiO2 + US in 4T1-bearing mice.
  • The review highlights one clinical example of SDT-based combination therapy: in three patients with metastatic breast cancer, SF1 + light + US improved tumors and vital signs to varying degrees; it also notes a separate case in which combined GcMAF, SDT, and exemestane led to complete disappearance of a patient’s right axillary tumor, pleural effusion, and pleural nodule.

## Methods

  • Narrative review of published studies on nanosonosensitizers-enhanced SDT for breast cancer, including mechanisms, nanosensitizer design, microenvironment modulation, imaging guidance, and combination therapies.
  • The review synthesizes preclinical cell and mouse studies across multiple breast cancer models, especially 4T1, MDA-MB-231, and MCF-7, plus a small number of clinical case reports/trials mentioned in the text.
  • Main analysis is qualitative: the authors compare strategies by mechanism and application, such as structural modification, targeted aggregation, TME modulation, imaging-guided therapy, and combinations with chemotherapy, immunotherapy, photodynamic therapy, photothermal therapy, ferroptosis, chemodynamic therapy, gas therapy, and gene therapy.

## Limitations

  • The paper explicitly states that many of the proposed approaches remain preclinical and that further preclinical studies and clinical trials are required to validate and improve SDT-based methods.
  • It notes that the precise working principle of SDT remains unclear and that mechanisms depend on cell type, model, sonosensitizer, and ultrasound parameters.
  • Evident from the text: this is a review article, so it does not present a new controlled experimental dataset of its own; instead, it summarizes heterogeneous studies with varied models, reagents, and ultrasound settings.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12951-025-03311-3

Cites

179 of 179 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Schematic illustration of the SDT mechanisms in breast cancer
Fig. 1 Schematic illustration of the SDT mechanisms in breast cancerCC BY · PubMed Central
Fig. 2 A The schematic diagram of the preparation of TBP@MOL for SDT. B The mechanism of enhanced 1O2 generation for TBP@MOL under ultrasound irradiation. Reprinted with permission from ref. [15]. Copyright 2023, Wiley. C Schematic illustration of the synthetic route of CTP and combined therapy. Reprinted with permission from ref. [50]. Copyright 2021, American Chemical Society. D Schematic illustration depicting the synthesis of M-BOC@SP NSs and mechanism of enhanced SDT against breast cancer. E Tumor volumes after various treatments (***P < 0.001). Reprinted with permission from ref. [16]. Copyright 2023, Elsevier. F Schematic illustration of energy bands of BWO-Fe NSs and band bending under ultrasound irradiation. G Fenton reactivity via Fe doping of BWO-Fe NSs improving sonodynamic performance.Reprinted with permission from ref. [54]. Copyright 2023, Wiley
Fig. 2 A The schematic diagram of the preparation of TBP@MOL for SDT. B The mechanism of enhanced 1O2 generation for TBP@MOL under ultrasound irradiation. Reprinted with permission from ref. [15]. Copyright 2023, Wiley. C Schematic illustration of the synthetic route of CTP and combined therapy. Reprinted with permission from ref. [50]. Copyright 2021, American Chemical Society. D Schematic illustration depicting the synthesis of M-BOC@SP NSs and mechanism of enhanced SDT against breast cancer. E Tumor volumes after various treatments (***P < 0.001). Reprinted with permission from ref. [16]. Copyright 2023, Elsevier. F Schematic illustration of energy bands of BWO-Fe NSs and band bending under ultrasound irradiation. G Fenton reactivity via Fe doping of BWO-Fe NSs improving sonodynamic performance.Reprinted with permission from ref. [54]. Copyright 2023, WileyCC BY · PubMed Central
Fig. 3 A Schematic illustration of the assembly of 1-NPs. B The mechanism of GSH-activatable sono-photodynamic immunotherapy for tumors by 1-NPs. Reprinted with permission from ref. [19]. Copyright 2023, Wiley. C Schematic diagram of the transformable TiO2@CaP under physiologically neutral as well as pathologically acidic condition and the mechanism for improved sono-immune therapeutic efficacy in tumor. D (a) Tumor weight of primary breast cancer and (b) tumor weight as well as (c) growth curves of metastatic lung cancer in 4T1 tumor-bearing mice with different treatments. Reprinted with permission from ref. [20]. Statistically significant difference: *P < 0.05; **P < 0.01; ***P < 0.001. Copyright 2021, Wiley. E The mechanism of efficient O2 production of MnO2/CaO2/Ce6@ZIF-8 for SDT. Reprinted with permission from ref. [68]. Copyright 2022, Royal Society of Chemistry
Fig. 3 A Schematic illustration of the assembly of 1-NPs. B The mechanism of GSH-activatable sono-photodynamic immunotherapy for tumors by 1-NPs. Reprinted with permission from ref. [19]. Copyright 2023, Wiley. C Schematic diagram of the transformable TiO2@CaP under physiologically neutral as well as pathologically acidic condition and the mechanism for improved sono-immune therapeutic efficacy in tumor. D (a) Tumor weight of primary breast cancer and (b) tumor weight as well as (c) growth curves of metastatic lung cancer in 4T1 tumor-bearing mice with different treatments. Reprinted with permission from ref. [20]. Statistically significant difference: *P < 0.05; **P < 0.01; ***P < 0.001. Copyright 2021, Wiley. E The mechanism of efficient O2 production of MnO2/CaO2/Ce6@ZIF-8 for SDT. Reprinted with permission from ref. [68]. Copyright 2022, Royal Society of ChemistryCC BY · PubMed Central
Fig. 4 A Schematic illustration for the design of FHMP NPs. B (a) PA images and (b) PA signal at tumor regions of MDA-MB-231 tumor-bearing mice with different treatment at varied time intervals. Reprinted with permission from ref. [74]. Copyright 2018, Ivyspring International Publisher. C A multifunctional Ce6/PFP/DTX/PLGA nanoparticle named CPDPNP with ultrasound imaging capabilities: (a) 2D and CEUS images under different low-intensity focused ultrasound intensities and duration times. The corresponding grayscale intensity of (b) B-mode and (c) CEUS imaging at different intensities and time (**P < 0.01). Reprinted with permission from ref. [75]. Copyright 2021, Springer. D Schematic illustration of the synthesis of HMONs-MnPpIX-PEG. E The axial and coronal T1-weighted MR imaging of 4T1 tumor-bearing mice (a) before and (b) after intravenous administration of HMONs-MnPpIX-PEG. F (a) axial and (b) coronal T1-weighted MRI signal intensity of tumor before and after the injection of HMONs-MnPpIX-PEG (**P < 0.01). Reprinted with permission from ref. [76]. Copyright 2017, American Chemical Society
Fig. 4 A Schematic illustration for the design of FHMP NPs. B (a) PA images and (b) PA signal at tumor regions of MDA-MB-231 tumor-bearing mice with different treatment at varied time intervals. Reprinted with permission from ref. [74]. Copyright 2018, Ivyspring International Publisher. C A multifunctional Ce6/PFP/DTX/PLGA nanoparticle named CPDPNP with ultrasound imaging capabilities: (a) 2D and CEUS images under different low-intensity focused ultrasound intensities and duration times. The corresponding grayscale intensity of (b) B-mode and (c) CEUS imaging at different intensities and time (**P < 0.01). Reprinted with permission from ref. [75]. Copyright 2021, Springer. D Schematic illustration of the synthesis of HMONs-MnPpIX-PEG. E The axial and coronal T1-weighted MR imaging of 4T1 tumor-bearing mice (a) before and (b) after intravenous administration of HMONs-MnPpIX-PEG. F (a) axial and (b) coronal T1-weighted MRI signal intensity of tumor before and after the injection of HMONs-MnPpIX-PEG (**P < 0.01). Reprinted with permission from ref. [76]. Copyright 2017, American Chemical SocietyCC BY · PubMed Central
Fig. 5 Summative scheme of combination therapy based on SDT for the treatment of breast cancer
Fig. 5 Summative scheme of combination therapy based on SDT for the treatment of breast cancerCC BY · PubMed Central
Fig. 6 A Synthesis of PSDL. B Cell uptake of nanoparticles using the red fluorescence emission of DOX by laser confocal microscope. C Tumor growth curves and D tumor photos of MDA-MB-231 tumor-bearing nude mice after different treatments. Reprinted with permission from ref. [17]. **P < 0.01, compared with control; ##P < 0.01, compared among groups. Copyright 2022, Multidisciplinary Digital Publishing Institute (MDPI). E Schematic demonstration of the synthesis of A-DPPs and chemotherapy and SDT combined therapy strategy. F The photos of 4T1-bearing mice and isolated tumors at day 15 post different treatments. G Tumor volumes and H survival curve of tumor-bearing mice after different therapies. ***P < 0.001, ****P < 0.0001. I The passive cavitation signals in tumor-bearing mice with different treatments. J Hematoxylin and eosin staining images of tumor sites to observe the coagulative necrosis areas in tumor-bearing mice with different treatments. Reprinted with permission from ref. [18]. Copyright 2022, Dove Press
Fig. 6 A Synthesis of PSDL. B Cell uptake of nanoparticles using the red fluorescence emission of DOX by laser confocal microscope. C Tumor growth curves and D tumor photos of MDA-MB-231 tumor-bearing nude mice after different treatments. Reprinted with permission from ref. [17]. **P < 0.01, compared with control; ##P < 0.01, compared among groups. Copyright 2022, Multidisciplinary Digital Publishing Institute (MDPI). E Schematic demonstration of the synthesis of A-DPPs and chemotherapy and SDT combined therapy strategy. F The photos of 4T1-bearing mice and isolated tumors at day 15 post different treatments. G Tumor volumes and H survival curve of tumor-bearing mice after different therapies. ***P < 0.001, ****P < 0.0001. I The passive cavitation signals in tumor-bearing mice with different treatments. J Hematoxylin and eosin staining images of tumor sites to observe the coagulative necrosis areas in tumor-bearing mice with different treatments. Reprinted with permission from ref. [18]. Copyright 2022, Dove PressCC BY · PubMed Central
Fig. 7 A Schematic illustration of the anti-tumor mechanism of CCL21a/ExoGM−CSF+Ce6@nanoGel. B Tumor growth (*P < 0.05 by two-way ANOVA) and C survival curves of 4T1 breast cancer mice treated with indicated hydrogels (*P < 0.01 by log-rank test). D The number of lung metastatic nodules at day 28 post different treatments (***P < 0.001 by one-way ANOVA). G1: None@nanoGel/US group; G2: CCL21a/ExoCtrl@nanoGel/US group; G3: CCL21a/ExoCtrl+Ce6@nanoGel/US group; G4: CCL21a/ExoGM−CSF+Ce6@nanoGel/US group. Reprinted with permission from ref. [94]. Copyright 2023, Wiley. E Schematic illustration of the synthesis of SnSNPs and their denaturation-and-penetration strategy for improved SDT. F The detection of content of collagen fibers via Masson’s trichrome staining of tumor tissue sections after various treatments. Reprinted with permission from ref. [97]. Copyright 2023, Nature Publishing Group
Fig. 7 A Schematic illustration of the anti-tumor mechanism of CCL21a/ExoGM−CSF+Ce6@nanoGel. B Tumor growth (*P < 0.05 by two-way ANOVA) and C survival curves of 4T1 breast cancer mice treated with indicated hydrogels (*P < 0.01 by log-rank test). D The number of lung metastatic nodules at day 28 post different treatments (***P < 0.001 by one-way ANOVA). G1: None@nanoGel/US group; G2: CCL21a/ExoCtrl@nanoGel/US group; G3: CCL21a/ExoCtrl+Ce6@nanoGel/US group; G4: CCL21a/ExoGM−CSF+Ce6@nanoGel/US group. Reprinted with permission from ref. [94]. Copyright 2023, Wiley. E Schematic illustration of the synthesis of SnSNPs and their denaturation-and-penetration strategy for improved SDT. F The detection of content of collagen fibers via Masson’s trichrome staining of tumor tissue sections after various treatments. Reprinted with permission from ref. [97]. Copyright 2023, Nature Publishing GroupCC BY · PubMed Central
Fig. 8 A Representative images of 4T1-bearing mice and B tumor weight from different groups at day 12 after treatments. **P < 0.01 versus control, ***P < 0.001 versus control, ##P < 0.01 SPDT/PSDT group versus SDT group, &&P < 0.01 SPDT/PSDT group versus PDT group. Reprinted with permission from ref. [108]. Copyright 2016, Elsevier. C Schematic illustration of PB + Ce6@Hy for self-augmented sonodynamic/photothermal combination therapy.Reprinted with permission from ref. [114]. Copyright 2022, Frontiers Media SA. D Schematic diagram of the preparation and anti-tumor mechanism of the CuS/HSA-TAPP. E Infrared thermal images and F temperature change curves of breast tumor-bearing mice with different treatments (**P < 0.01). G Tumor volume of breast tumor-bearing mice on the 14th day after different treatments. I: PBS group; II: Laser group; III:US group, IV: CuS/HSA hollow nanocapsules group, V: CuS/HSA hollow nanocapsules + laser group, VI: CuS/HSA hollow nanocapsules + US group, VII: CuS/HSA hollow nanocapsules + US + laser group, VIII: CuS/HSA-TAPP hollow nanocapsules group, IX: CuS/HSA-TAPP hollow nanocapsules + laser group, X: CuS/HSA-TAPP hollow nanocapsules + US group, XI: CuS/HSA-TAPP hollow nanocapsules + US + laser group. Reprinted with permission from ref. [115]. Copyright 2022, Royal Society of Chemistry
Fig. 8 A Representative images of 4T1-bearing mice and B tumor weight from different groups at day 12 after treatments. **P < 0.01 versus control, ***P < 0.001 versus control, ##P < 0.01 SPDT/PSDT group versus SDT group, &&P < 0.01 SPDT/PSDT group versus PDT group. Reprinted with permission from ref. [108]. Copyright 2016, Elsevier. C Schematic illustration of PB + Ce6@Hy for self-augmented sonodynamic/photothermal combination therapy.Reprinted with permission from ref. [114]. Copyright 2022, Frontiers Media SA. D Schematic diagram of the preparation and anti-tumor mechanism of the CuS/HSA-TAPP. E Infrared thermal images and F temperature change curves of breast tumor-bearing mice with different treatments (**P < 0.01). G Tumor volume of breast tumor-bearing mice on the 14th day after different treatments. I: PBS group; II: Laser group; III:US group, IV: CuS/HSA hollow nanocapsules group, V: CuS/HSA hollow nanocapsules + laser group, VI: CuS/HSA hollow nanocapsules + US group, VII: CuS/HSA hollow nanocapsules + US + laser group, VIII: CuS/HSA-TAPP hollow nanocapsules group, IX: CuS/HSA-TAPP hollow nanocapsules + laser group, X: CuS/HSA-TAPP hollow nanocapsules + US group, XI: CuS/HSA-TAPP hollow nanocapsules + US + laser group. Reprinted with permission from ref. [115]. Copyright 2022, Royal Society of ChemistryCC BY · PubMed Central
Fig. 9 A Schematic illustration of IRP NPs for ferroptosis-boosted sonodynamic antitumor therapy. B Western blot and relative quantitative analysis of (a and b) Caspase-3, (c and d) GPX4 and (e and f) HIF-1α (**P < 0.01, ***P < 0.001, ****P < 0 .0001). Reprinted with permission from ref. [119]. Copyright 2022, Taylor &Francis. C Schematic diagram of SAFE mediated combination treatment of sonodynamic therapy and ferroptosis. D The tumor volumes curves of the 4T1 orthotopic breast tumors with different treatments (***P < 0.001). E Histological analysis of tumor tissues for ROS, TUNEL, caspase-3, HIF-1α and GPX4. Reprinted with permission from ref. [120]. Copyright 2022, Wiley
Fig. 9 A Schematic illustration of IRP NPs for ferroptosis-boosted sonodynamic antitumor therapy. B Western blot and relative quantitative analysis of (a and b) Caspase-3, (c and d) GPX4 and (e and f) HIF-1α (**P < 0.01, ***P < 0.001, ****P < 0 .0001). Reprinted with permission from ref. [119]. Copyright 2022, Taylor &Francis. C Schematic diagram of SAFE mediated combination treatment of sonodynamic therapy and ferroptosis. D The tumor volumes curves of the 4T1 orthotopic breast tumors with different treatments (***P < 0.001). E Histological analysis of tumor tissues for ROS, TUNEL, caspase-3, HIF-1α and GPX4. Reprinted with permission from ref. [120]. Copyright 2022, WileyCC BY · PubMed Central
Fig. 10 A Schematic diagram of ROS generation by Cu2-xO-BTO NCs through the sonodynamic and chemodynamic processes and detection by the specific probes. B The detection of 1O2 in the sonodynamic process via degradation curves of DPBF. C The production of ⋅OH in the sonodynamic process measured by using TA as the probe. D Generation of ⋅OH in the chemodynamic process measured by using TMB as the probe. Reprinted with permission from ref. [124]. Copyright 2022, American Chemical Society. E The expression of HK2 and Glut1 in 4T1 tumor-bearing mice by immunochemistry. F Images of pulmonary metastatic nodules of breast cancer. Reprinted with permission from ref. [131]. Copyright 2019, Elsevier. G Schematic illustration of T-mTNPs@L-Arg for synergistic nitric oxide gas-sonodynamic therapy. H The relative dissolved oxygen content in the cell medium of different groups. I The tumor volumes curves (*P < 0.05 versus mTNPs@L-Arg) and J Tumor weight of the MCF-7 tumor-bearing mice with different treatments (*P < 0.05 versus the control groups, #P < 0.05 versus mTNPs@L-Arg). Reprinted with permission from ref. [132]. Copyright 2022, Dove Press
Fig. 10 A Schematic diagram of ROS generation by Cu2-xO-BTO NCs through the sonodynamic and chemodynamic processes and detection by the specific probes. B The detection of 1O2 in the sonodynamic process via degradation curves of DPBF. C The production of ⋅OH in the sonodynamic process measured by using TA as the probe. D Generation of ⋅OH in the chemodynamic process measured by using TMB as the probe. Reprinted with permission from ref. [124]. Copyright 2022, American Chemical Society. E The expression of HK2 and Glut1 in 4T1 tumor-bearing mice by immunochemistry. F Images of pulmonary metastatic nodules of breast cancer. Reprinted with permission from ref. [131]. Copyright 2019, Elsevier. G Schematic illustration of T-mTNPs@L-Arg for synergistic nitric oxide gas-sonodynamic therapy. H The relative dissolved oxygen content in the cell medium of different groups. I The tumor volumes curves (*P < 0.05 versus mTNPs@L-Arg) and J Tumor weight of the MCF-7 tumor-bearing mice with different treatments (*P < 0.05 versus the control groups, #P < 0.05 versus mTNPs@L-Arg). Reprinted with permission from ref. [132]. Copyright 2022, Dove PressCC BY · PubMed Central

Verification

Claims the paper makes

36 Valid · 2 Not valid · 41 Not checked · 30 Own results and interpretations

41 more claims · 5 with their cited sources checked

Create a free account to see all 109 claims and to verify the 5 references still open.

See all claims — free account
  • Probably not a substantial claim. 19
  • It may state two separate claims as one. 48

Create a free account to see these claims.

Citations

Cites

Show all 179 references

Research works printed but not linked: 2

  1. Breast Cancer Treatment (PDQ(R)). Health Professional Version. PDQ cancer information summaries. Bethesda: Breast Cancer Treatment; 2023.
  2. Ning S, Lyu M, Zhu D, Lam JWY, Huang Q, Zhang T, et al. Type-I AIE Photosensitizer Loaded Biomimetic System Boosting Cuproptosis to Inhibit Breast Cancer Metastasis and Rechallenge. ACS Nano. 2023;17(11):10206–10217. · DOI · Paper page

Cited by

See all 43

Metadata

Authors
Yu, J., Hu, J.-R., Tian, Y., Lei, Y.-M., Hu, H.-M., Lei, B.-S., Zhang, G., Sun, Y., & Ye, H.-R.
Affiliations
  • Wuhan University of Science and Technology (CN)
  • Huazhong University of Science and Technology (CN)
  • Hubei University of Technology (CN)
  • Central China Normal University (CN)
Corresponding author
  • Lei, Bing-Song
  • Zhang, Ge
  • Sun, Yao
  • Ye, Hua-Rong
Venue
Journal of Nanobiotechnology
Published
2025-04-07
Volume
23
Issue
1
Pages
281-281
ISSN
1477-3155 (ISSN-L)
OpenAlex
W4409212576
Cited by
43
References
179
Citations by year
2026: 31 · 2025: 12
FWCI
3.45
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Nanobiotechnology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Natural Science Foundation of Hubei Province (2022CFA033)
  • Wuhan University
  • Wuhan University of Science and Technology
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
  • Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
Keywords
sonodynamic therapy, breast cancer, sonosensitizer, reactive oxygen species, tumor microenvironment, image-guided therapy, sono-photodynamic therapy, multimodal cancer therapy, clinical translation
MeSH terms
Animals, Breast Neoplasms, Female, Humans, Immunotherapy, Photochemotherapy, Ultrasonic Therapy, Reactive Oxygen Species, Nanomedicine, Nanoparticles, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nanosensitizer-assisted sonodynamic therapy for breast cancer. https://app.cochat.ai/papers/10.1186/s12951-025-03311-3
The paper
Yu, J., Hu, J.-R., Tian, Y., Lei, Y.-M., Hu, H.-M., Lei, B.-S., Zhang, G., Sun, Y., & Ye, H.-R. (2025). Nanosensitizer-assisted sonodynamic therapy for breast cancer. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-025-03311-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.